期刊文献+

青年脑梗死患者纤溶系统和蛋白C系统变化的特点 被引量:3

Chatacteristics of changes in fibrinolysis and protein C system in young adults with cerebral infarction
暂未订购
导出
摘要 目的:探讨青年脑梗死患者血浆纤溶活性和蛋白C系统变化及其临床意义。方法:临床收集25例青年脑梗死患者、29例对照者血液标本,采用产色法测定血浆纤溶酶原、(plasminogenactivator,PA)、(plasminogenactivatorinhibitor-1,PAI-1)活性,比浊法测定蛋白C和蛋白S活性,同时常规测定血脂水平。结果:①青年脑梗死组(1.10±0.43)IU和皮质支脑梗死组(0.99±0.48)IU血浆PA活性较对照组(1.46±0.50)IU显著降低(分别t=2.777,P=0.008;t=2.932,P=0.006)。皮质支脑梗死组PAI-1活性(2.30±0.59)IU较腔隙性梗死组(2.97±0.93)IU低(t=2.074,P=0.049)。②青年脑梗死组血浆蛋白S和蛋白C水平与对照组相比,无明显差异。③多元统计分析结果显示:PA和高血压对青年脑梗死的发生有显著作用。结论:PA和高血压分别是青年脑梗死患者的独立危险因素。 AIM:To investigate the changes of plasma fibrinolysis and protein C systems in young patients with cerebral infarction and their clinical significance. METHODS:Blood samples were collected from 25 young patients with cerebral infarction and 29 controls. Activities of plasminogen, plasminogen activator(PA) and plasminogen activator inhibitor 1(PAI 1) were determined by chromogenic substrate assay,and protein C activities were measured by turbidimetry. RESULTS:PA activity in the young patients with cerebral infarction[(1.10±0.43)IU]and with cortical infarction[(0.99±0.48)IU]both decreased significantly as compared with that in the controls[(1.46±0.50) IU](t=2.777,P=0.008;t=2.932,P=0.006 respectively ). PAI 1 activity in the patients with cortical infarction[(2.30±0.59) IU]was lower than that in the patients with lacunar infarction[(2.97±0.93) IU](t=2.074,P=0.049). There were no significant differences in the levels of protein C and protein S between the patients and controls.Multivariate statistical analysis indicated that PA and hypertension played a remarkable role in the occurrence of cerebral infarction in the young adult. CONCLUSION:Both PA activity and hypertension are important risk factors for cerebral infarction in the young adult.
出处 《中国临床康复》 CSCD 2004年第10期1888-1889,共2页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献18

  • 1张颍冬,刘锡民,蔡转,杨明山.脑梗塞早期患者血纤溶系统活性状态分析[J].中华内科杂志,1995,34(8):518-521. 被引量:14
  • 2肖迎春,张敏芳,郑安.急性脑卒中所致抑郁症的相关因素[J].中国临床康复,2003,7(5):795-795. 被引量:16
  • 3Harabi Y, DooIman R, Rosenthal T, et al. Homoeysteine levels in hypertensive patients with a history of cadiac or cerebral atherothrombotic events. Am J Hypertens I999; 12:766-71.
  • 4Stchouwur DA, Weijenberg PM, Vanden B, et al. Serum homocysteine and risk of coronary, heart disease and cerebrovascular disease in elderly men, A 10-year-follow-up. Arterioscler Thromb Vasc Biol I998: 18: 1895- 901.
  • 5Folsom AR, Aleksic N, Park E, et al. Prospective study of fibrinolytic factors and incident coronary heart disease: The atherosclerosls risk in communities(ARIC)study. Arterioscler Thromb Vasc Biol 2001 : 21 (4) : 611 - 7.
  • 6Lindgren A, Lindoff C, Norrving B, et al. Tissue plasminogen activator and plasminogen activator inhibitor-Ⅰ in stroke patients. Stroke 1996: 27:1066 -71.
  • 7Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand 1998(2): 124 -7.
  • 8Tosetto A, Ruggeri M, Castaman G, et al. Inherited abnormalities of blood coagulation in juvenile stroke. A case-control study. Blood Coagul Fibrinolysis 1997;8(7): 397 -402.
  • 9Chaturvedi S, Dzieczkowski J. Muhiplehemostatic abnormalities in young adults with activated protein C resistance and cerebral ischemia. J Neurol Sci 1998; 159(2): 209-12.
  • 10陈兴活,张坚洪.皮层与穿支脑梗死患者血脂水平对日常生活活动能力的影响[J].中国临床康复,2003,7(3):406-407. 被引量:3

二级参考文献11

共引文献31

同被引文献22

  • 1梁子钧.血液流变学及其在医学临床上的应用[J].生理科学进展,1979,10:304-304.
  • 2Moe SE, Sorbo JG, Sogaard R, et al. New isofoms ofrat A'quapo- rin-4 [J]. Cenomics, 2008, 91 (4): 367-377.
  • 3Kawasaki H, Altieri DC, Lu CD. Inhibition of apoptosis by surviv- hag predicts shorter survival rates ha coloreetal cancer [J]. Cancer Kes, 1998, 58: 5071.
  • 4Shimanuki Y, Takahashi K, Cui R, el al. Role of serum vascular endo- thelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer [J]. Lung, 2005, 183 (1): 29-42.
  • 5施永德.缺血性中风先兆预防和预防性治疗的初步探讨[J].中华医学杂志,1979,4:710-710.
  • 6Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999; 892:146-54
  • 7Comuzzie AG, Funahashi T, Sonnenberg G, et al. The genetic basis of plasma variation in adiponectin, a global endopheno type for obesity and the metabolic.Syndrome. J Clin Endocrinol Metab 2001; 86:4321 - 5
  • 8Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002: 25:376 - 80
  • 9Fasshauer M, Klein J, Neumann S, et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001;507(2):142 -6
  • 10Hotta K, FunahashiT, Bodkin NL, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys . Diabetes 2001; 50:1126 - 33

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部